Additionally, a meta-analysis by Hosseinpour et al. (17) including GLP-1 RAs studies such as semaglutide showed GLP-1 RAs outperformed placebo for MACE, all-cause death, cardiovascular death, myocardial infarction, stroke, and HF hospitalization. The gene discussed is GLP1R; the disease is myocardial infarction.